Eli Lilly Total Cost of Revenue increased by 6.1% to $3.58B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 60.8%, from $2.23B to $3.58B. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows an upward trend with a 10.9% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.95B | $1.43B | $2.05B | $2.07B | $1.43B | $1.58B | $1.55B | $1.63B | $1.81B | $1.86B | $1.79B | $1.67B | $2.17B | $2.17B | $2.40B | $2.23B | $2.45B | $3.01B | $3.37B | $3.58B |
| QoQ Change | — | -26.7% | +43.3% | +1.1% | -31.0% | +10.4% | -2.0% | +5.1% | +11.1% | +2.9% | -3.9% | -6.4% | +29.7% | +0.0% | +10.7% | -7.4% | +10.0% | +22.9% | +12.1% | +6.1% |
| YoY Change | — | — | — | — | -26.8% | +10.4% | -24.5% | -21.5% | +26.3% | +17.8% | +15.5% | +2.9% | +20.1% | +16.7% | +34.4% | +33.0% | +12.8% | +38.6% | +40.3% | +60.8% |
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Reportable Segment | $2.23B | $2.45B | $3.01B | $3.37B | $3.58B |
| Total | $2.23B | $2.45B | $3.01B | $3.37B | $3.58B |